Detalhe da pesquisa
1.
Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation.
Blood
; 137(23): 3212-3217, 2021 06 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33720354
2.
Genetically modified IL2 bone-marrow-derived myeloid cells reprogram the glioma immunosuppressive tumor microenvironment.
Cell Rep
; 42(8): 112891, 2023 Aug 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-37516967
3.
Single-cell RNA sequencing reveals immunosuppressive myeloid cell diversity during malignant progression in a murine model of glioma.
Cell Rep
; 42(3): 112197, 2023 03 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-36871221
4.
Simplified mass cytometry protocol for in-plate staining, barcoding, and cryopreservation of human PBMC samples in clinical trials.
STAR Protoc
; 3(2): 101362, 2022 06 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-35573480
5.
Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma.
Transplant Cell Ther
; 28(1): 32.e1-32.e10, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34670169
6.
Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial.
J Immunother Cancer
; 9(11)2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34772758
7.
Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival.
J Immunother Cancer
; 9(9)2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34593617
8.
High-Throughput Mass Cytometry Staining for Immunophenotyping Clinical Samples.
STAR Protoc
; 1(2): 100055, 2020 09 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-33111099